|
BP16041
|
Gliquidone
|
|
|
|
|
Gliquidone is a potent, second-generation sulfonylurea with antihyperglycemic activity. Like other second-generation compounds, gliquidone exerts greater binding affinity to SUR1 and increased potency compared to first-generation compounds. In addition, this agent exerts peroxisome proliferator-activated receptor (PPAR) gamma agonistic activity.
|
|
BP16042
|
Gossypetin
|
|
|
|
|
Gossypetin has anti-mutagenic, anti-atherosclerotic, antioxidant, as well as cytoprotective and antimicrobial effects, it inhibits bone resorption through down-regulating lysosomal cathepsin K activity and autophagy-related protein induction in actin ring-bearing osteoclasts.
|
|
BP16043
|
GSK-7975A
|
|
|
|
|
GSK-7975A is a potent and orally available inhibitor of CRAC channel.
|
|
BP16044
|
GW791343 dihydrochloride
|
|
|
|
|
GW791343 dihydrochloride is a P2X7 allosteric modulator.
|
|
BP16045
|
GW791343 trihydrochloride
|
|
|
|
|
GW791343 HCl is aHCl salt form of GW791343, which is a non-competitive allosteric modulator of human P2X7 receptor inhibitor with pIC50 of 7.
|
|
BP16046
|
H3B-120
|
|
|
|
|
H3B-120 is a highly selective, competitive, and allosteric carbamoyl phosphate synthetase 1 (CPS1) inhibitor (IC50: 1.5 μM; Ki: 1.4 μM) with anti-cancer activity.
|
|
BP16047
|
Halazone
|
|
|
|
|
Halazone is fine white powder with an odor of chlorine. It has been widely used to disinfect drinking water.
|
|
BP16048
|
IC87201
|
|
|
|
|
IC87201 is a nNOS-PDZ/PSD-95-PDZ inhibitor. IC87201 showed great promise in cellular experiments and animal models of ischemic stroke and pain.
|
|
BP16049
|
ICA-121431
|
|
|
|
|
ICA-121431 is a nanomolar potent small molecule Nav1.7 channel inhibitor with IC50 of 19 nM for rat Nav1.7, with little or no activity against human Nav1.5 or Nav1.7 channels.
|
|
BP16050
|
ICILIN
|
|
|
|
|
Icilin(AG 3-5) is a synthetic TRPM8 ion channel super-agonist.
|
|
BP16051
|
Ifenprodil Tartrate
|
|
|
|
|
Ifenprodil is a selective NMDA receptor (glutamate) antagonist.
|
|
BP16052
|
Indazole
|
|
|
|
|
Indazole, also called benzpyrazole or isoindazone, is a heterocyclic aromatic organic compound. Indazole derivatives display a broad variety of biological activities.
|
|
BP16053
|
Iptakalim Hydrochloride
|
|
|
|
|
Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist. Iptakalim is also a K(ir) 6.1/SUR2B activator that can attenuate hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.
|
|
BP16054
|
Isopulegol
|
|
|
|
|
Isopulegol presents depressant- and anxiolytic-like effects, it also has anticonvulsant and bioprotective effects against PTZ-induced convulsions are possibly related to positive modulation of benzodiazepine-sensitive GABAA receptors and to antioxidant properties.Isopulegol presents significant gastroprotective effects in both ethanol- and indomethacin-induced ulcer models, which appear to be mediated, at least in part, by endogenous prostaglandins, K(ATP) channel opening, and antioxidant properties.
|
|
BP16055
|
Isotanshinone I
|
|
|
|
|
Isotanshinone I with IC50s of 1.13 μM and 0.432 μM for α-glucosidase and AGE, respectively. Isotanshinone I has inhibitory activity against α-glucosidase and formation of AGE,
|
|
BP16056
|
Jatrophane 5
|
|
|
|
|
Jatrophane 5 demonstrates the most powerful inhibition of P-gp, higher than R(+)-verapamil and tariquidar in colorectal multi-drug resistant (MDR) cells (DLD1-TxR).
|
|
BP16057
|
JNJ-47965567
|
|
|
|
|
JNJ-47965567 is a selective antagonist of the purinergic receptor P2X subtype 7 (P2X7), a ligand-gated ion channel(with pKis of 7.9 and 8.7 for human and rat P2X7, respectively).
|
|
BP16058
|
KM 91104
|
|
|
|
|
KM 91104 is a cell permeable inhibitor of V-ATPase. KM91104 specifically targets the interaction between V-ATPase subunit A3 and subunit B2.
|
|
BP16059
|
KPT185
|
|
|
|
|
KPT-185 is a selective CRM1 inhibitor, inducing apoptosis, cell-cycle arrest.
|
|
BP16060
|
KPT276
|
|
|
|
|
KPT-276 is an orally bioavailable selective inhibitor of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of CRM1.
|
